These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21504387)

  • 1. Solanezumab for Alzheimer's disease.
    Samadi H; Sultzer D
    Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?
    Tayeb HO; Murray ED; Price BH; Tarazi FI
    Expert Opin Biol Ther; 2013 Jul; 13(7):1075-84. PubMed ID: 23574434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.
    Imbimbo BP; Ottonello S; Frisardi V; Solfrizzi V; Greco A; Seripa D; Pilotto A; Panza F
    Expert Rev Clin Immunol; 2012 Feb; 8(2):135-49. PubMed ID: 22288451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward.
    Panza F; Solfrizzi V; Imbimbo BP; Tortelli R; Santamato A; Logroscino G
    Expert Rev Clin Immunol; 2014 Mar; 10(3):405-19. PubMed ID: 24490853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
    Panza F; Solfrizzi V; Imbimbo BP; Logroscino G
    Expert Opin Biol Ther; 2014 Oct; 14(10):1465-76. PubMed ID: 24981190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibodies against β-amyloid (Aβ) for the treatment of Alzheimer's disease: the Aβ target at a crossroads.
    Panza F; Frisardi V; Imbimbo BP; Seripa D; Solfrizzi V; Pilotto A
    Expert Opin Biol Ther; 2011 Jun; 11(6):679-86. PubMed ID: 21501112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease.
    Panza F; Solfrizzi V; Imbimbo BP; Giannini M; Santamato A; Seripa D; Logroscino G
    Expert Rev Neurother; 2014 Sep; 14(9):973-86. PubMed ID: 25081412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?
    Panza F; Logroscino G; Imbimbo BP; Solfrizzi V
    Curr Opin Psychiatry; 2014 Mar; 27(2):128-37. PubMed ID: 24445401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
    Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
    Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.
    Panza F; Frisardi V; Imbimbo BP; D'Onofrio G; Pietrarossa G; Seripa D; Pilotto A; Solfrizzi V
    Immunotherapy; 2010 Nov; 2(6):767-82. PubMed ID: 21091109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease.
    Lozupone M; Dibello V; Sardone R; Castellana F; Zupo R; Lampignano L; Bortone I; Stallone R; Altamura M; Bellomo A; Daniele A; Solfrizzi V; Panza F
    Expert Opin Drug Discov; 2024 Jun; 19(6):639-647. PubMed ID: 38685682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.
    Siemers ER; Friedrich S; Dean RA; Gonzales CR; Farlow MR; Paul SM; Demattos RB
    Clin Neuropharmacol; 2010; 33(2):67-73. PubMed ID: 20375655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid beta peptide immunotherapy in Alzheimer disease.
    Delrieu J; Ousset PJ; Voisin T; Vellas B
    Rev Neurol (Paris); 2014 Dec; 170(12):739-48. PubMed ID: 25459121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease.
    Doggrell SA
    Expert Opin Biol Ther; 2018 Dec; 18(12):1189-1192. PubMed ID: 30376649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?
    Cedernaes J; Schiöth HB; Benedict C
    Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More failure with solanezumab - this time in preclinical Alzheimer's disease.
    Doggrell SA
    Expert Opin Biol Ther; 2024 Mar; 24(3):119-123. PubMed ID: 38414336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset.
    Panza F; Seripa D; Lozupone M; Solfrizzi V; Imbimbo BP; Barulli MR; Tortelli R; Capozzo R; Bisceglia P; Dimitri A; Stallone R; Dibello V; Quaranta N; Daniele A; Bellomo A; Greco A; Logroscino G
    Expert Opin Biol Ther; 2018 Jan; 18(1):25-35. PubMed ID: 29037101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies for Alzheimer's disease treatment: An overview of anti-amyloid beta monoclonal antibodies.
    Rygiel K
    Indian J Pharmacol; 2016; 48(6):629-636. PubMed ID: 28066098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy for Alzheimer's disease].
    Falkentoft AC; Hasselbalch SG
    Ugeskr Laeger; 2016 Jan; 178(3):V07150588. PubMed ID: 26815584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.